Startup profile for Valar Labs: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.
Venture Capital Tracker logo
Venture Capital Tracker

Startup profile · funding coverage

Valar Labs funding, valuation and investors

Computational pathology AI predicting cancer therapy response from H&E slides.

Keep track of Valar Labs

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Series A

$22M · May 2024

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$26M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

series a · San Francisco, California

Investors in latest funding

Lead: Andreessen Horowitz

Other: Pear VC

Sources: latest funding Last verified: 2026-07-25

Overview

Valar Labs develops computational histology AI that predicts how patients will respond to cancer therapies using standard H&E pathology slides — no proprietary staining required. Its CHAI (Computational Histology AI) platform trains models on digitized slides to guide therapy selection in urologic and other solid tumors. Founded by Stanford researchers, Valar raised a $4M seed led by a16z in 2022 and a $22M Series A in May 2024 co-led by a16z Bio+Health and DCVC with Pear VC participating.

Why Valar Labs is interesting

CHAI tests like Vesta for bladder cancer turn standard pathology slides into treatment-selection signals — precision oncology without new wet-lab assays.

Product & use cases

Valar's CHAI platform analyzes digitized H&E pathology slides with deep learning to predict treatment response and risk stratification. The workflow integrates with existing hospital pathology pipelines — slides already collected for diagnosis become predictive inputs without additional lab tests.

  • Bladder cancer therapy selection using CHAI-Vesta predictive models on standard slides
  • Oncology teams prioritizing immunotherapy vs. chemotherapy based on computational histology scores
  • Clinical trials enriching cohorts with slide-based biomarkers absent from genomic panels

Key facts

  • Series A (May 2024): $22M co-led by a16z Bio+Health and DCVC; Pear VC participated — Business Wire
  • Seed (2022): $4M led by a16z — a16z announcement
  • CHAI platform predicts cancer therapy response from standard H&E pathology slides

Funding history (newest first)

Series A

2024-05 $22M

Source: https://www.businesswire.com/news/home/20240501000000/en/Valar-Labs-Series-A

Seed

2022 $4M

Source: https://a16z.com/announcement/investing-in-valar-labs

Investors in our directory

Funds linked from Valar Labs's profile — open a fund page for stage focus and related deal articles.

Andreessen Horowitz Pear VC

Competitive landscape

Edge: Using ubiquitous H&E slides lowers adoption friction vs. companies requiring new assays (IHC panels, NGS). Valar's clinical validation path on specific indications (e.g., bladder) creates regulatory and evidence moats.

Computational pathology is crowded, but therapy-response prediction on standard slides is a narrower, high-value claim. Valar must produce clinical evidence per indication (FDA pathway TBD per product). Paige and PathAI have broader diagnostic footprints; Valar's wedge is actionable treatment decisions from existing slides. a16z Bio+Health and DCVC co-lead signals bio+AI conviction.

  • Paige AI direct

    Digital pathology AI broadly; Valar emphasizes therapy-response prediction on H&E.

  • Tempus adjacent

    Genomics-first oncology platform; Valar adds slide-native signals without sequencing.

  • PathAI direct

    Pathology AI for diagnosis and trials; overlapping hospital slide workflows.

  • Guardant Health adjacent

    Liquid biopsy genomics; different sample type but same therapy-selection buyer.

Notable stories

  • Valar's CHAI-Vesta test targets bladder cancer — named to reflect validated predictive signal on standard slides without new biomarker assays (Business Wire, 2024).
  • Founders spun Valar from Stanford computational pathology research, betting digitized slide archives are an underused training corpus (a16z investment announcement).

Industries

Healthtech Biotech & Life Sciences AI & Machine Learning

Related funding articles

Venture Capital Tracker pieces that cover Valar Labs's financing or category context.

FAQs about Valar Labs

Practical answers founders, operators, and investors typically search for.

Valar Labs builds computational histology AI (CHAI) that predicts cancer therapy response from standard H&E pathology slides — integrating with existing hospital pathology workflows.
Andreessen Horowitz (/fund/andreessen-horowitz) led seed ($4M, 2022) and co-led Series A ($22M, 2024) with DCVC. Pear VC (/fund/pear-vc) participated in Series A.
CHAI (Computational Histology AI) is Valar's platform analyzing digitized pathology slides to generate therapy-response predictions and risk scores.
Valar uses standard H&E slides already collected for diagnosis — no proprietary staining or sequencing required for its core workflow.
Public materials emphasize urologic oncology including bladder cancer (CHAI-Vesta). Additional indications may be in development.
Valar announced a $22M Series A in May 2024 per Business Wire.
Tempus leads with genomic sequencing and data platform. Valar adds slide-based computational histology predictions without requiring NGS.
Regulatory status varies by product and indication — consult Valar's official disclosures and FDA databases for current clearances.
San Francisco Bay Area; Stanford-affiliated founding team.
No public profitability disclosure. Clinical-stage healthtech company.
Website All startups Funding news

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.